Effects of Progestin on Modulation of the Expression of Biomarkers in Endometriosis.
CD44
endometriosis
immunohistochemistry
osteopontin
progestin
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 Jul 2023
20 Jul 2023
Historique:
received:
21
06
2023
revised:
11
07
2023
accepted:
18
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Our study aimed to examine the osteopontin (OPN) serum levels and tissue expression of CD44 and OPN in endometriosis-affected women both undergoing and not undergoing progestin treatment, and also to determine their involvement in the pathogenesis of endometriosis. Using an ELISA kit, we evaluated the OPN serum levels of healthy and endometriosis-affected women both undergoing and not undergoing progestin treatment. Immunohistochemical (IHC) analyses were used to assess the endometriotic tissue expressions of CD44 and OPN. There were statistically significant higher OPN serum levels in the healthy control group compared to the women with endometriosis. Furthermore, there were higher OPN serum levels in the endometriosis-affected women undergoing the progestin treatment, but the difference did not reach statistical significance. In comparison to OPN, CD44 expression was significantly higher in all the endometriotic tissue glands and stroma, regardless of the patient's treatment status. Compared to the group receiving therapy, the OPN levels were higher in the endometriosis group not receiving therapy. OPN's robust cytoplasmic expression seemed to be associated with the non-treatment group. Endometriosis, CD44, and OPN appear to be closely related. This study suggests that endometriosis that has not been treated has an immunological profile distinct to endometriosis that has received treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Our study aimed to examine the osteopontin (OPN) serum levels and tissue expression of CD44 and OPN in endometriosis-affected women both undergoing and not undergoing progestin treatment, and also to determine their involvement in the pathogenesis of endometriosis.
METHODS
METHODS
Using an ELISA kit, we evaluated the OPN serum levels of healthy and endometriosis-affected women both undergoing and not undergoing progestin treatment. Immunohistochemical (IHC) analyses were used to assess the endometriotic tissue expressions of CD44 and OPN.
RESULTS
RESULTS
There were statistically significant higher OPN serum levels in the healthy control group compared to the women with endometriosis. Furthermore, there were higher OPN serum levels in the endometriosis-affected women undergoing the progestin treatment, but the difference did not reach statistical significance. In comparison to OPN, CD44 expression was significantly higher in all the endometriotic tissue glands and stroma, regardless of the patient's treatment status. Compared to the group receiving therapy, the OPN levels were higher in the endometriosis group not receiving therapy. OPN's robust cytoplasmic expression seemed to be associated with the non-treatment group.
CONCLUSION
CONCLUSIONS
Endometriosis, CD44, and OPN appear to be closely related. This study suggests that endometriosis that has not been treated has an immunological profile distinct to endometriosis that has received treatment.
Identifiants
pubmed: 37509675
pii: biomedicines11072036
doi: 10.3390/biomedicines11072036
pmc: PMC10377117
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clinicoecon Outcomes Res. 2020 Aug 26;12:473-479
pubmed: 32922052
J Obstet Gynaecol Res. 2019 Nov;45(11):2260-2266
pubmed: 31411797
Reprod Sci. 2021 Feb;28(2):435-446
pubmed: 32909189
Int Immunol. 2023 Apr 4;35(4):171-180
pubmed: 36525591
Int J Mol Med. 2013 May;31(5):1011-6
pubmed: 23545719
Am J Reprod Immunol. 2009 Apr;61(4):286-93
pubmed: 19260859
J Nutr Biochem. 2020 Dec;86:108486
pubmed: 32827666
J Minim Invasive Gynecol. 2012 Jul-Aug;19(4):514-6
pubmed: 22748956
J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):55-63
pubmed: 23962574
Acta Obstet Gynecol Scand. 2002 Mar;81(3):195-203
pubmed: 11966474
Am J Reprod Immunol. 2007 Oct;58(4):330-43
pubmed: 17845203
Diseases. 2021 Feb 04;9(1):
pubmed: 33557369
Gynecol Oncol. 2021 Sep;162(3):741-750
pubmed: 34247767
Mol Cancer Ther. 2010 Jan;9(1):57-66
pubmed: 20053761
J Psychosom Obstet Gynaecol. 2017 Dec;38(4):238-248
pubmed: 28635533
Fertil Steril. 2016 Dec;106(7):1552-1571.e2
pubmed: 27817837
J Reprod Med. 2007 Mar;52(3):207-13
pubmed: 17465288
Lancet. 2004 Nov 13-19;364(9447):1789-99
pubmed: 15541453
Int J Mol Sci. 2021 Sep 28;22(19):
pubmed: 34638843
J Minim Invasive Gynecol. 2017 Jan 1;24(1):114-123
pubmed: 27693809
Sci Rep. 2019 Jun 25;9(1):9272
pubmed: 31239500
J Mol Med (Berl). 2020 Dec;98(12):1713-1725
pubmed: 33047155
Schmerz. 2016 Oct;30(5):477-490
pubmed: 27681777
CMAJ. 2023 Mar 14;195(10):E363-E371
pubmed: 36918177
J Steroid Biochem Mol Biol. 2018 Apr;178:150-158
pubmed: 29229305
J Transl Med. 2020 Aug 12;18(1):311
pubmed: 32787880
Reprod Fertil Dev. 2021 Feb;33(4):257-269
pubmed: 33541520
Reprod Biomed Online. 2021 Jul;43(1):139-147
pubmed: 34049811
Reprod Sci. 2016 Jan;23(1):87-91
pubmed: 26169039
Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:68-91
pubmed: 29530425
Front Bioeng Biotechnol. 2022 Jul 01;10:918368
pubmed: 35845410
Int J Mol Sci. 2022 Dec 05;23(23):
pubmed: 36499654
J Dent Res. 2015 Dec;94(12):1638-45
pubmed: 26341976
BMC Med Genomics. 2022 Oct 31;15(1):225
pubmed: 36316684
J Clin Diagn Res. 2015 Jun;9(6):ZE10-3
pubmed: 26266236
Reprod Sci. 2017 May;24(5):773-782
pubmed: 27678100
Hum Reprod. 2016 Apr;31(4):712-22
pubmed: 26851604
Minerva Med. 2015 Apr;106(2):95-108
pubmed: 25517500
Cell Death Dis. 2018 Mar 2;9(3):356
pubmed: 29500465
Obstet Gynecol Sci. 2013 Mar;56(2):102-9
pubmed: 24327988
Reprod Biol Endocrinol. 2015 Aug 20;13:95
pubmed: 26289107
Cochrane Database Syst Rev. 2016 May 01;(5):CD012179
pubmed: 27132058
Int J Nanomedicine. 2016 Mar 30;11:1323-36
pubmed: 27099493
Front Surg. 2021 Dec 06;8:791686
pubmed: 34938768
Int J Reprod Med. 2014;2014:179515
pubmed: 25763392
PLoS One. 2016 Mar 28;11(3):e0152302
pubmed: 27018976
BMC Cancer. 2019 Apr 29;19(1):401
pubmed: 31035965
Mol Pathol. 1999 Aug;52(4):189-96
pubmed: 10694938
PLoS One. 2017 Sep 28;12(9):e0185346
pubmed: 28957406
Taiwan J Obstet Gynecol. 2020 Nov;59(6):916-921
pubmed: 33218412
FASEB J. 2020 Oct;34(10):13125-13139
pubmed: 32830349
Int J Gynecol Pathol. 2001 Apr;20(2):140-6
pubmed: 11293159
Arch Gynecol Obstet. 2015 Feb;291(2):383-90
pubmed: 25129125
Pathol Res Pract. 2016 Jan;212(1):10-6
pubmed: 26608413
Reprod Biol Endocrinol. 2020 Nov 20;18(1):116
pubmed: 33218351
J Clin Endocrinol Metab. 2010 Jul;95(7):3437-45
pubmed: 20410224
Reprod Sci. 2014 Jan;21(1):82-8
pubmed: 23653392